Conversio Health Recalls Albuterol and Ipratropium Vials Due to Processing Controls
Conversio Health is recalling Albuterol 2.5mg / Ipratropium 0.75mg vials nationwide due to a lack of processing controls.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 2/5 (Moderate).
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II, and the source text does not report any illnesses or injuries, fitting the criteria for a moderate severity voluntary precautionary recall.
Plain-English summary
Integrated Health Concepts Inc. dba Conversio Health is recalling Albuterol 2.5mg / Ipratropium 0.75mg, 2ML Vials, For Inhalation Only. The recall is being conducted due to a lack of processing controls.
The affected product was distributed nationwide in the U.S. All lots of the product are included in this recall.
Consumers should stop using the product and contact their healthcare provider or the recalling firm for further instructions.
The recalled product
- Product
- Albuterol 2.5mg / Ipratropium 0.75mg, 2ML Vial, For Inhalation Only, Conversio Health, San Luis Obispo, CA 93401.
- Category
- Drug — Inhalation Medication
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- All Lots
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 10 recalled by Integrated Health Concepts Inc. dba Conversio Health under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 10 products in this recall →Related recalls
Same manufacturer · Integrated Health Concepts Inc. dba Conversio Health
See all →- ModerateConversio Health Recalls Budesonide Inhalation Vials Due to Processing Control Issues
FDA (Drugs) · 2019-11-27
- ModerateConversio Health Recalls Albuterol and Ipratropium Inhalation Vials
FDA (Drugs) · 2019-11-27
- ModerateConversio Health Recalls Albuterol and Ipratropium Vials Due to Processing Controls
FDA (Drugs) · 2019-11-27
- ModerateConversio Health Recalls Albuterol and Ipratropium Inhalation Vials
FDA (Drugs) · 2019-11-27
- ModerateConversio Health Recalls Albuterol, Ipratropium, and Budesonide Inhalation Vials
FDA (Drugs) · 2019-11-27
Same hazard · processing controls
See all →- HighCompounded tirzepatide 8.8 mg vials recalled over lack of processing controls
FDA (Drugs) · 2025-08-13
- HighCompounded tirzepatide 11.24 mg vials recalled over lack of processing controls
FDA (Drugs) · 2025-08-13
- HighCompounded semaglutide 0.22 mg vials recalled over lack of processing controls
FDA (Drugs) · 2025-08-13
- HighCompounded semaglutide 0.44 mg vials recalled over lack of processing controls
FDA (Drugs) · 2025-08-13
- HighCompounded tirzepatide 4.4 mg vials recalled over lack of processing controls
FDA (Drugs) · 2025-08-13
Similar recalls
- SevereWise Pharmacy Recalls Compounded Papaverine Injectable Due to Processing Controls
FDA (Drugs) · 2019-08-07
- Moderate
- SevereKroger Specialty Pharmacy Recalls Albuterol Inhalation Solution Due to Processing Controls
FDA (Drugs) · 2018-05-16
- ModerateWise Pharmacy Recalls Alprostadil Injectable Due to Lack of Processing Controls
FDA (Drugs) · 2019-08-07
- ModerateWise Pharmacy Recalls Papaverine/Phentolamine Injectable Due to Processing Controls
FDA (Drugs) · 2019-08-07
- ModerateWise Pharmacy Recalls Papaverine, Phentolamine, and Alprostadil Injectable Vials
FDA (Drugs) · 2019-08-07